Seborrhoeic dermatitis — DVA SoP factors

Reasonable Hypothesis (RH) — Statement of Principles No. 43 of 2021

At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting seborrhoeic dermatitis or death from seborrhoeic dermatitis with the circumstances of a person's relevant service:

1. (1)
   having infection with human immunodeficiency virus before the clinical onset of seborrhoeic dermatitis;
2. (2)
   having infection with human T-cell lymphotropic virus type-1 before the clinical onset of seborrhoeic dermatitis;
3. (3)
   having Parkinson's disease or secondary parkinsonism at the time of the clinical onset of seborrhoeic dermatitis;
4. (4)
   having a physical disability or psychiatric disease which significantly limits the person's ability to maintain personal hygiene of the affected area at the time of the clinical onset of seborrhoeic dermatitis;

   Note: Examples of conditions which can significantly limit a person's ability to maintain personal hygiene include severe injuries, paralysis, immobility, alcohol use disorder and major depressive disorder.

5. (5)
   being immobile for at least the four weeks before the clinical onset of seborrhoeic dermatitis;

   Note: Examples of being immobile include being in intensive care, having a spinal cord injury and, for facial seborrhoeic dermatitis, having facial paralysis.

6. (6)
   having received a solid organ transplant at the time of the clinical onset of seborrhoeic dermatitis;
7. (7)
   taking a drug from the specified list of drugs for the treatment of cancer or autoimmune disease for at least the seven days before the clinical onset of seborrhoeic dermatitis;

   Note: specified list of drugs is defined in the Schedule 1 - Dictionary.

8. (8)
   taking a drug which is associated in the individual with the clinical onset of seborrhoeic dermatitis during drug therapy and either: (a) the improvement of seborrhoeic dermatitis within three months of discontinuing or tapering drug therapy; or (b) the redevelopment of seborrhoeic dermatitis on rechallenge with the same drug; and where taking the drug continued for at least the seven days before the clinical onset of seborrhoeic dermatitis;
9. (9)
   having infection with human immunodeficiency virus before the clinical worsening of seborrhoeic dermatitis;
10. (10)
    having infection with human T-cell lymphotropic virus type-1 before the clinical worsening of seborrhoeic dermatitis;
11. (11)
    having Parkinson's disease or secondary parkinsonism at the time of the clinical worsening of seborrhoeic dermatitis;
12. (12)
    having a physical disability or psychiatric disease which significantly limits the person's ability to maintain personal hygiene of the affected area at the time of the clinical worsening of seborrhoeic dermatitis;

    Note: Examples of conditions which can significantly limit a person's ability to maintain personal hygiene include severe injuries, paralysis, immobility, alcohol use disorder and major depressive disorder.

13. (13)
    being immobile for at least the four weeks before the clinical worsening of seborrhoeic dermatitis;

    Note: Examples of being immobile include being in intensive care, having a spinal cord injury and, for facial seborrhoeic dermatitis, having facial paralysis.

14. (14)
    having received a solid organ transplant at the time of the clinical worsening of seborrhoeic dermatitis;
15. (15)
    taking a drug from the specified list of drugs for the treatment of cancer or autoimmune disease for at least the seven days before the clinical worsening of seborrhoeic dermatitis;

    Note: specified list of drugs is defined in the Schedule 1 - Dictionary.

16. (16)
    taking a drug which is associated in the individual with the clinical worsening of seborrhoeic dermatitis during drug therapy and either: (a) the improvement of seborrhoeic dermatitis within three months of discontinuing or tapering drug therapy; or (b) the worsening of seborrhoeic dermatitis on rechallenge with the same drug; and where taking the drug continued for at least the seven days before the clinical worsening of seborrhoeic dermatitis;
17. (17)
    wearing a surgical mask or face covering intended to provide protection from human-to-human respiratory virus transmission, for a cumulative period of at least 20 hours in the seven days before the clinical worsening of seborrhoeic dermatitis;
18. (18)
    inability to obtain appropriate clinical management for seborrhoeic dermatitis;

Aggravation-only factors: the factors in subsections 9(9) to 9(18) apply only to material contribution to, or aggravation of, the condition where it was suffered or contracted before or during (but did not arise out of) the person’s relevant service.